Rachlis A - Search Results

1

Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.

Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS. Loutfy MR, et al. Among authors: rachlis a. HIV Clin Trials. 2007 Sep-Oct;8(5):259-68. doi: 10.1310/hct0805-259. HIV Clin Trials. 2007. PMID: 17956827 Clinical Trial.

2

Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, Rachlis A, Phillips E, Rubin G, Gough K, Walmsley S. Loutfy M, et al. Among authors: rachlis a. HIV Clin Trials. 2003 Sep-Oct;4(5):301-10. doi: 10.1310/7LYW-GQFF-WPRQ-K3QW. HIV Clin Trials. 2003. PMID: 14583846

3

Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study.

Rachlis A, Gill J, Baril JG, LeBlanc RP, Trottier B, MacLeod J, Walmsley S, Van der Vliet W, Belsky G, Burgoyne R. Rachlis A, et al. HIV Clin Trials. 2005 Jul-Aug;6(4):203-12. doi: 10.1310/2bjl-j62n-bfjx-4995. HIV Clin Trials. 2005. PMID: 16323322 Clinical Trial.

4

Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis.

Walmsley SL, Raboud J, Angel JB, Mazzulli T, Shen S, Casciaro L, Young CD, Moussa G, Gough K, Rachlis A, Hopkins J. Walmsley SL, et al. Among authors: rachlis a. HIV Clin Trials. 2006 Jan-Feb;7(1):1-9. doi: 10.1310/9M23-QN0X-W6N8-80JD. HIV Clin Trials. 2006. PMID: 16632459 Clinical Trial.

5

Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors.

Loutfy MR, Macdonald S, Myhr T, Husson H, Du Mont J, Balla S, Antoniou T, Rachlis A. Loutfy MR, et al. Among authors: rachlis a. Antivir Ther. 2008;13(1):87-95. doi: 10.1177/135965350801300109. Antivir Ther. 2008. PMID: 18389902

6

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. Cescon AM, et al. Among authors: rachlis a. HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8. HIV Med. 2011. PMID: 21059167 Free article.

7

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.

Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, Milan D, Shen A, Klein MB, Cooper C, Machouf N, Rourke SB, Rachlis A, Tsoukas C, Montaner JS, Walmsley SL, Smieja M, Bayoumi A, Mills E, Hogg RS; CANOC Collaboration. Loutfy MR, et al. Among authors: rachlis a. J Acquir Immune Defic Syndr. 2010 Dec;55(4):451-9. doi: 10.1097/qai.0b013e3181ec28ff. J Acquir Immune Defic Syndr. 2010. PMID: 21105259

8

Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada.

Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, Rueda S, Rachlis A, Wobeser W, Macarthur RD, Binder L, Rosenes R, Loutfy MR. Andany N, et al. Among authors: rachlis a. HIV Clin Trials. 2011 Mar-Apr;12(2):89-103. doi: 10.1310/hct1202-89. HIV Clin Trials. 2011. PMID: 21498152

9

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration. Tan DH, et al. J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc. J Acquir Immune Defic Syndr. 2011. PMID: 21709570

10

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.

Cooper C, Rollet-Kurhajec KC, Young J, Vasquez C, Tyndall M, Gill J, Pick N, Walmsley S, Klein MB; Canadian Co-infection Cohort Study Investigators. Cooper C, et al. HIV Med. 2015 Jan;16(1):24-31. doi: 10.1111/hiv.12168. Epub 2014 May 18. HIV Med. 2015. PMID: 24837567 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

277 results

Search Page